1. ICO Information Centre on HPV and Cancer, authors. Philippines Human Papillomavirus and Related Cancers Fact Sheet 2016;
December 15, 2016.
2. Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
3. Muoz N, Bosch FX, de Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical
cancer. N Engl J Med. 2003;348:518527.
4. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218226.
5.Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
6. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer, 54: 594-
606, 1993.
7. Chao A., Becker T. M., Jordan S. W., Darling R., Gilliland F. D., Key C. R. Decreasing rates of cervical cancer among American
Indians and Hispanics in New Mexico (United States). Cancer Causes Control, 7:205-213, 1996.
8. Arizona Cancer Registry, Arizona Department of Health Services, Phoenix, AZ, 1995.
9. CDC surveillance summary. Trends in cancer screeningUnited States, 19871992. Morbid. Mortal. Wkly. Rep., 45: 57-91, 1995.
10. Kurman R. J., Henson D. E., Herbst A. L., Noller K. L., Schiffman M. H. Interim guidelines for management of abnormal cervical
cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 272: 1866-1869, 1994.
infection. These are smoking, multiple sexual partners, and early age of first
having sex (sexual intercourse).
1. ICO Information Centre on HPV and Cancer, authors. Philippines Human Papillomavirus and Related Cancers Fact Sheet 2016;
December 15, 2016.
2. Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
3. Muoz N, Bosch FX, de Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical
cancer. N Engl J Med. 2003;348:518527.
4. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218226.
5.Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
6. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer, 54: 594-
606, 1993.
7. Chao A., Becker T. M., Jordan S. W., Darling R., Gilliland F. D., Key C. R. Decreasing rates of cervical cancer among American
Indians and Hispanics in New Mexico (United States). Cancer Causes Control, 7:205-213, 1996.
8. Arizona Cancer Registry, Arizona Department of Health Services, Phoenix, AZ, 1995.
9. CDC surveillance summary. Trends in cancer screeningUnited States, 19871992. Morbid. Mortal. Wkly. Rep., 45: 57-91, 1995.
10. Kurman R. J., Henson D. E., Herbst A. L., Noller K. L., Schiffman M. H. Interim guidelines for management of abnormal cervical
cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 272: 1866-1869, 1994.
United States and North America. Among Hispanics in the United States, the
rate of cervical cancer has decreased significantly in some states7,
presumably due to the implementation of aggressive Pap smear screening
programs. In the other states, such as Arizona, Hispanic women experience a
higher rate of cervical cancer compared with non-Hispanic white women
(10.4 versus 7.5/100,000; ref. 8). In addition, minority women in the United
States experience a disproportionately high burden 8 of the >2 million yearly
cases of the precursor SILs.10 Although amenable to treatment, low- and
high-grade SILs add a significant economic burden to the health care system
due to the need for diagnostic follow-up and treatment of these lesions.
1. ICO Information Centre on HPV and Cancer, authors. Philippines Human Papillomavirus and Related Cancers Fact Sheet 2016;
December 15, 2016.
2. Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
3. Muoz N, Bosch FX, de Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical
cancer. N Engl J Med. 2003;348:518527.
4. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218226.
5.Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
6. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer, 54: 594-
606, 1993.
7. Chao A., Becker T. M., Jordan S. W., Darling R., Gilliland F. D., Key C. R. Decreasing rates of cervical cancer among American
Indians and Hispanics in New Mexico (United States). Cancer Causes Control, 7:205-213, 1996.
8. Arizona Cancer Registry, Arizona Department of Health Services, Phoenix, AZ, 1995.
9. CDC surveillance summary. Trends in cancer screeningUnited States, 19871992. Morbid. Mortal. Wkly. Rep., 45: 57-91, 1995.
10. Kurman R. J., Henson D. E., Herbst A. L., Noller K. L., Schiffman M. H. Interim guidelines for management of abnormal cervical
cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 272: 1866-1869, 1994.
There are two vaccinations against cervical cancer, the Cervarix and Gardasil.
The Cervarix (GlaxoSmithKline, Philadelphia, PA) is an L1 VLP vaccine
against HPV 16 and 18, which is also given as a series of three injections (0,
1 and 6 months). While, Gardasil (Merck & Co., Inc., Whitehouse Station,
NJ) is a prophylactic quadrivalent vaccine against HPV types 6, 11, 16 and 18
made from noninfectious virus like particles (VLPs) and it is given as a series
of 3 injections over a 6-month period (at 0, 2 and 6 months).
1. ICO Information Centre on HPV and Cancer, authors. Philippines Human Papillomavirus and Related Cancers Fact Sheet 2016;
December 15, 2016.
2. Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
3. Muoz N, Bosch FX, de Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical
cancer. N Engl J Med. 2003;348:518527.
4. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218226.
5.Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
6. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer, 54: 594-
606, 1993.
7. Chao A., Becker T. M., Jordan S. W., Darling R., Gilliland F. D., Key C. R. Decreasing rates of cervical cancer among American
Indians and Hispanics in New Mexico (United States). Cancer Causes Control, 7:205-213, 1996.
8. Arizona Cancer Registry, Arizona Department of Health Services, Phoenix, AZ, 1995.
9. CDC surveillance summary. Trends in cancer screeningUnited States, 19871992. Morbid. Mortal. Wkly. Rep., 45: 57-91, 1995.
10. Kurman R. J., Henson D. E., Herbst A. L., Noller K. L., Schiffman M. H. Interim guidelines for management of abnormal cervical
cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 272: 1866-1869, 1994.
In the results of the study, over half of the sample (54%) was accepting of
HPV vaccination at the low price, but only 30% and 31% were accepting at
the moderate and high price, respectively. Negative intent to receive the
vaccine was significantly associated with womens indication that their
mothers or partners were influential in their vaccination decisions. Percieved
social support, access to transportation, perceived benefits of vaccination,
perceived susceptibility to HPV, history of pap testing and having been
exposed to vaccine-promoting media were among factors independently
associated with positive intent to receive the vaccine.
1. ICO Information Centre on HPV and Cancer, authors. Philippines Human Papillomavirus and Related Cancers Fact Sheet 2016;
December 15, 2016.
2. Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
3. Muoz N, Bosch FX, de Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical
cancer. N Engl J Med. 2003;348:518527.
4. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218226.
5.Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
6. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer, 54: 594-
606, 1993.
7. Chao A., Becker T. M., Jordan S. W., Darling R., Gilliland F. D., Key C. R. Decreasing rates of cervical cancer among American
Indians and Hispanics in New Mexico (United States). Cancer Causes Control, 7:205-213, 1996.
8. Arizona Cancer Registry, Arizona Department of Health Services, Phoenix, AZ, 1995.
9. CDC surveillance summary. Trends in cancer screeningUnited States, 19871992. Morbid. Mortal. Wkly. Rep., 45: 57-91, 1995.
10. Kurman R. J., Henson D. E., Herbst A. L., Noller K. L., Schiffman M. H. Interim guidelines for management of abnormal cervical
cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 272: 1866-1869, 1994.
The researchers concluded that Filipina women accepted HPV vaccination if
the price is affordable. They also added that to achieve successful vaccine
initiative in the region, it must minimize the structural barriers, foster familial
and social support for vaccination, incorporate HPV education and work
within cultural norms.
1. ICO Information Centre on HPV and Cancer, authors. Philippines Human Papillomavirus and Related Cancers Fact Sheet 2016;
December 15, 2016.
2. Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
3. Muoz N, Bosch FX, de Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical
cancer. N Engl J Med. 2003;348:518527.
4. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218226.
5.Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
6. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer, 54: 594-
606, 1993.
7. Chao A., Becker T. M., Jordan S. W., Darling R., Gilliland F. D., Key C. R. Decreasing rates of cervical cancer among American
Indians and Hispanics in New Mexico (United States). Cancer Causes Control, 7:205-213, 1996.
8. Arizona Cancer Registry, Arizona Department of Health Services, Phoenix, AZ, 1995.
9. CDC surveillance summary. Trends in cancer screeningUnited States, 19871992. Morbid. Mortal. Wkly. Rep., 45: 57-91, 1995.
10. Kurman R. J., Henson D. E., Herbst A. L., Noller K. L., Schiffman M. H. Interim guidelines for management of abnormal cervical
cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 272: 1866-1869, 1994.
REFERENCES:
April M. Young et al. (2010). HPV vaccine acceptability among women in the
Philippines.
1. ICO Information Centre on HPV and Cancer, authors. Philippines Human Papillomavirus and Related Cancers Fact Sheet 2016;
December 15, 2016.
2. Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
3. Muoz N, Bosch FX, de Sanjos S, et al. Epidemiologic classification of human papillomavirus types associated with cervical
cancer. N Engl J Med. 2003;348:518527.
4. Winer RL, Lee S-K, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female
university students. Am J Epidemiol. 2003;157:218226.
5.Centers for Disease Control and Prevention, authors. Genital HPV Infection Fact Sheet. Rockville, MD: CDC National Prevention
Information Network; 2004.
6. Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985.Int. J. Cancer, 54: 594-
606, 1993.
7. Chao A., Becker T. M., Jordan S. W., Darling R., Gilliland F. D., Key C. R. Decreasing rates of cervical cancer among American
Indians and Hispanics in New Mexico (United States). Cancer Causes Control, 7:205-213, 1996.
8. Arizona Cancer Registry, Arizona Department of Health Services, Phoenix, AZ, 1995.
9. CDC surveillance summary. Trends in cancer screeningUnited States, 19871992. Morbid. Mortal. Wkly. Rep., 45: 57-91, 1995.
10. Kurman R. J., Henson D. E., Herbst A. L., Noller K. L., Schiffman M. H. Interim guidelines for management of abnormal cervical
cytology. The 1992 National Cancer Institute Workshop. J. Am. Med. Assoc., 272: 1866-1869, 1994.